Johnson & Johnson (NYSE:JNJ) received FDA Fast Track designation for nipocalimab as a potential treatment for systemic lupus ...

Bristol-Myers Squibb (NYSE:BMY) reported positive top-line Phase 2 results for Reblozyl in alpha-thalassemia related anemia, covering both non-transfusion and transfusion-dependent patients. The ...

Although major pharmaceutical companies have fallen in line with President Donald Trump’s “most favored nation” (MFN) drug pricing agenda, the specifics of their negotiated concessions and the actu | ...

Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive ...

Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or ...